A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor

Essential Tremor Clinical Trial

Official title:

A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03253991
• Other study ID #: ET002J
• Status: Terminated
• Phase: N/A
• Start date: November 17, 2014
• Est. completion date: February 2, 2023

Study information

• Verified date: April 2023
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects The objective of this prospective, single-arm study is to test the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor inpatients with essential tremor (ET). The Indications for Use claim for this system is as follows: Treatment of medication-refractory tremor in patients with essential tremor.

Description:

The objective of this prospective, multi-site, single-arm study is to test the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in subjects with essential tremor (ET). Safety: To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate Transcranial MRgFUS treatment of medication-refractory ET Effectiveness: To determine the effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory tremor (i.e. ET). Efficacy will be determined utilizing the Clinical Rating Scale for Tremor (CRST) in ET from examinations at baseline and 3-Months post-ExAblate treatment. • This study is designed as a prospective, multi-site, single-arm study. Assessments of primary efficacy endpoints will compare the three months after ExAblate treatment to Baseline measurements for clinical symptom relief. Safety of ExAblate in the treatment of ET will be collected for one year after ExAblate treatment. Relative Safety will be evaluated using a common description of Significant Clinical Complications for patients treated in this study. This study will be performed on the 3T MR scanners. The secondary endpoints of the study are as follows: 1. Quality life claims: Questionnaire for Essential Tremor (QUEST) outcome (upper extremity questions) at Months 3 change from Baseline 2. Durability (as measured by QUEST upper arm extremity questions) of the procedure as reflected by the efficacy data through change from baseline measures through Month 12 follow up 3. Subject daily functionalities: as measured by CRST Part-C (subscales)Month 12 as compared to Baseline.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 154
• Est. completion date: February 2, 2023
• Est. primary completion date: February 2, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 99 Years

Eligibility

Inclusion Criteria

• Men and women age 22 years or older
• A diagnosis of ET as confirmed from clinical history and examination by a neurologist or neurosurgeon specialized in movement disorder
• Have had an inadequate response to one or two oral doses of medication, per local standards. An inadequate medication trial is defined as a therapeutic dose of each medication and poor response to drug, or the development of side effects as the medication dose is titrated.
• Able to communicate sensations during the ExAblate TcMRgFUS treatment

Exclusion criteria:

• Subjects with unstable cardiac status
• Severe hypertension (diastolic BP > 100 on medication)
• Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
• Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease
• Patient with severely impaired renal function
• History of abnormal bleeding and/or coagulopathy
• History of immunocompromise including those who are HIV positive.
• History of intracranial hemorrhage
• Cerebrovascular disease (multiple CVA or CVA within 6 months)
• Subjects with uncontrolled symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, papilledema).
• Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (can be up to 4 hrs of total table time.)
• Are participating or have participated in another clinical trial in the last 30 days
• Significant claustrophobia that cannot be managed with mild medication.
• Presence of any other neurodegenerative disease such as Parkinson-plus syndromes suspected on neurological examination.
• Presence of significant cognitive impairment
• Subjects with life-threatening systemic disease
• Subjects with a history of seizures within the past year
• Subjects with presence or history of psychosis

Related Conditions & MeSH terms

• Essential Tremor
• Tremor

Intervention

Device:
• MRgFUS treatment
ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing
China	Henan Provincial People's Hospital	Zhengzhou	Henan
Japan	Sadamoto Hospital	Ehime
Japan	Shonan Fujisawa Tokushukai Hospital	Fujisawa
Japan	Hokkaido Ohno Memorial Hospital	Hokkaido
Japan	Hokuto	Hokkaido
Japan	Ohanishi Noerological Center	Hyogo
Japan	Kumagaya General Hospital	Kumagaya
Japan	Department of Neurosurgery, Osaka University Hospital	Osaka
Japan	Tokyo Women's Medical University Hospital	Tokyo
Taiwan	Chang Bing Show Chwan Memorial Hospital	Chang Hua

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Countries where clinical trial is conducted

China,  Japan,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety - Will be determined evaluating incidence and severity of device related complications from first treatment day visit through all follow ups. Relative Safety will be evaluated describing Significant Clinical Complications for patients treated.	All AEs will be reported and categorized by investigators as definitely, probably, possibly, or unrelated to the device or procedure and categorized by treatment group / treatment arm. Relative Safety will be evaluated using a common description of Significant Clinical Complications for patients treated in this study.	1 year
Primary	Effectiveness - Will be evaluated using the Clinical Rating Scale for Tremors (CRST) for ET subjects. Comparison will be performed from examinations at baseline and 3-Months post-ExAblate treatment.	Assessments of efficacy endpoints will compare the three months after ExAblate treatment to Baseline measurements for clinical symptom relief.	5 Years